Sarepta Therapeutics, Inc.
SRPTNasdaqCIK 873303HealthcareFiscal year ends Dec 31
Reports and events: 345 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-08-0516:06 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-335056 |
| 2026-08-0516:01 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001193125-26-335003 |
| 2026-07-2709:08 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-316995 |
| 2026-06-0416:29 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-257501 |
| 2026-05-0616:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-208966 |
| 2026-05-0616:01 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001193125-26-208893 |
| 2026-04-2416:10 ET | DEF 14A | Proxy statementPeriod 2026-06-04 | 0001193125-26-177247 |
| 2026-03-0207:02 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001193125-26-084144 |
| 2026-02-2517:09 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-26-072064 |
| 2026-02-2516:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-071566 |
| 2026-01-1212:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-010116 |
| 2025-12-1916:34 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001193125-25-326969 |
| 2025-12-1107:13 ET | 8-K | 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-315032 |
| 2025-12-0807:33 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-25-310588 |
| 2025-11-0616:02 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001193125-25-269436 |
| 2025-11-0316:18 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-262591 |
| 2025-08-2916:18 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-192794 |
| 2025-08-2107:07 ET | 8-K | 3.02 Unregistered sale of equity | 0001193125-25-184625 |
| 2025-08-1517:28 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0000950170-25-109461 |
| 2025-08-1316:10 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-25-179819 |
| 2025-08-0616:02 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0000950170-25-103971 |
| 2025-07-2107:30 ET | 8-K | 8.01 Other events | 0001193125-25-161516 |
| 2025-07-1616:11 ET | 8-K | 2.02 Results of operations; 2.05 Exit or disposal costs; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0000950170-25-096257 |
| 2025-06-0616:30 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0000950170-25-083131 |
| 2025-05-0616:01 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0000950170-25-064412 |
| 2025-04-2416:05 ET | DEF 14A | Proxy statementPeriod 2025-06-05 | 0000950170-25-058003 |
| 2025-02-2816:01 ET | 10-K | Annual reportPeriod 2024-12-31 | 0000950170-25-029973 |
| 2025-02-2616:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-027717 |
| 2025-02-1417:23 ET | SCHEDULE 13D | Ownership report, active investor | 0000950170-25-021481 |
| 2025-02-1408:38 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001193125-25-026683 |
| 2025-01-1312:25 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-005160 |
| 2024-11-2607:17 ET | 8-K | 1.01 Entry into a material agreement | 0001193125-24-265627 |
| 2024-11-0616:01 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0000950170-24-122239 |
| 2024-09-1608:51 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0000950170-24-106619 |
| 2024-08-0716:01 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0000950170-24-092720 |
| 2024-06-0716:45 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-24-157458 |
| 2024-05-0116:01 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0000950170-24-051234 |
| 2024-04-2416:05 ET | DEF 14A | Proxy statementPeriod 2024-06-06 | 0000950170-24-047570 |
| 2024-02-2816:01 ET | 10-K | Annual reportPeriod 2023-12-31 | 0000950170-24-022036 |
| 2024-01-0812:08 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-24-002822 |
| 2023-11-0116:01 ET | 10-Q | Quarterly reportPeriod 2023-09-30 | 0000950170-23-057414 |
| 2023-08-0216:02 ET | 10-Q | Quarterly reportPeriod 2023-06-30 | 0000950170-23-037125 |
| 2023-06-2216:49 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-23-029438 |
| 2023-06-2214:22 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-23-029354 |
| 2023-06-0916:29 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0000950170-23-027276 |
| 2023-05-0216:02 ET | 10-Q | Quarterly reportPeriod 2023-03-31 | 0000950170-23-016654 |
| 2023-04-2416:08 ET | DEF 14A | Proxy statement | 0000950170-23-014085 |
| 2023-03-0307:31 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001193125-23-058990 |
| 2023-02-2816:04 ET | 10-K | Annual reportPeriod 2022-12-31 | 0000950170-23-005062 |
| 2023-01-0913:40 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-23-000495 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 14:58 ET. Listed shows no prices and gives no investment advice.